Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
92 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-10-01
Study Completion Date
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical study is to evaluate the effects of a personalized symptomatic treatment plan integrated with monthly telemedicine and mobile palliative care interventions on a population of individuals diagnosed with Multiple System Atrophy (MSA) and their informal caregivers. The aim is to improve the quality of life of MSA patients and their caregivers, as well as provide them with better support during the disease progression.
After a baseline visit, all 46 patients will receive a personalized therapeutic plan (including medical treatment, physiotherapy, logotherapy and occupational therapy excercises and psychological support) and contact with social workers and a palliative care team. They willl then be re-evaluated at 6-,12-, 18- month visits. Semi-structured online interviews at baseline and 12 month visit will collect patients' individual healthcare preferences, which will be taken into account in the preparation of the individual therapeutic plan. Twenty-three patients will be randomized to receive monthly telemedicine visits. Assessment of patients´satisfaction with the therapeutic plan, with the palliative interventions (when they occurred) and the telemedicine visits will be carried over the 18 month period.
Forty-six informal caregivers will be invited to participate with semi-structured online interviews and assessment of their QoL and caregivers' burden.
After a baseline visit, all 46 patients will receive a personalized therapeutic plan (including medical treatment, physiotherapy, logotherapy and occupational therapy excercises and psychological support) and contact with social workers and a palliative care team. They willl then be re-evaluated at 6-,12-, 18- month visits. Semi-structured online interviews at baseline and 12 month visit will collect patients' individual healthcare preferences, which will be taken into account in the preparation of the individual therapeutic plan. Twenty-three patients will be randomized to receive monthly telemedicine visits. Assessment of patients´satisfaction with the therapeutic plan, with the palliative interventions (when they occurred) and the telemedicine visits will be carried over the 18 month period.
Forty-six informal caregivers will be invited to participate with semi-structured online interviews and assessment of their QoL and caregivers' burden.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
NCT05949580
Relapsing Remitting Multiple Sclerosis
RECRUITING
Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration
NCT06223074
Multiple Sclerosis Relapsing Remitting
Treatment
ENROLLING_BY_INVITATION
PHASE2
Remote MS Care in Antwerp
NCT06179758
Multiple Sclerosis
ACTIVE_NOT_RECRUITING
NA
Decision Making in Multiple Sclerosis Care Under Uncertainty
NCT04035720
Multiple Sclerosis
UNKNOWN
NA
Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis
NCT04233970
Multiple Sclerosis, Relapsing-Remitting
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a monocentric, 18-months, randomized, rater-blinded study to evaluate the influence of a multidisciplinary, personalized symptomatic treatment plan with integrated mobile palliative care and telemedicine on the baseline to 18-months change in the QoL of individuals with MSA compared to a sex-, age- and disease-duration matched historical European MSA cohort, whose data is stored at the Medical University of Innsbruck.
We plan to recruit 46 individuals with MSA fulfilling all the inclusionand none of the exclusion criteria. Upon collection of written informed consent, the recruited individuals will be instructed to complete a falls protocol referred to the month preceding the baseline visit, as well as a blood pressure (BP), bladder diary for up to 72 hours prior to the baseline visit. They will subsequently undergo a baseline examination including a comprehensive clinical, psychological and neuro-rehabilitation assessment, as well as an online semi-structured interview aimed at pinpointing the individual therapeutic needs and healthcare preferences. In case additional examinations are needed, these will be carried out on the same day of the baseline visit or, if not possible for individual or appointment reasons, at the earliest possible time point within the given timeframe as outlined in the visit schedule. Upon completion of the baseline visit and examinations, the individualized therapeutic plan, including mobile palliative care offer (for wheelchair-bound individuals) and guidance for self-practiced physio-, speech and occupational exercises will be prepared based on a standardized operational protocol drafted by the study team on the basis of published consensus recommendations, scientific evidence and principles of good clinical practice and adapted to the individual healthcare preferences and therapeutic needs of the recruited individuals.
Six, 12 and 18 months after the baseline visit, in-person visits will be scheduled, including a comprehensive clinical, psychological and neuro-rehabilitation re-assessment of the individual therapeutic needs. Therapeutic adaptations will be made following the standardized operational protocol and adapted to the individual healthcare preferences. In the event that the enrolled subjects are for legitimate reasons unable to travel to hospital, they will be offered the opportunity to complete the scheduled on-site assessments of month 6, 12, and 18 using the CHES online platform.
At month 12 the online semi-structured interview will be repeated to assess for eventual changes in the individual healthcare preferences due to the disease progression.
At month 1, 7 and 13, follow-up phone calls will be scheduled to verify the compliance with the individualized treatment plan and identify barriers to its application.
At month 1, 7, 13 and 18, the study participants will be invited to complete online satisfaction surveys with the overall individualized treatment plan.
Twenty-three patients will be block-wise randomized to receive additional monthly and on-demand neurological, psychological, physio-, occupational and speech therapy (based on individual needs) telemedicine visits through the CHES teleconsultation facility of the Tirol Kliniken.
Upon completion of the telemedicine visit (or on-demand mobile palliative interventions, for wheelchair-bound individuals, whenever needed and wished), brief satisfaction surveys will be sent to the study participants through the CHES platform.
Informal caregivers of the individuals with MSA recruited in the present study will be invited to participate upon written informed consent in an 18 months observational study, with baseline and 12 months semi-structured online interviews and baseline, 6-, 12- and 18 months assessment of their QoL and caregivers' burden.
We plan to recruit 46 individuals with MSA fulfilling all the inclusionand none of the exclusion criteria. Upon collection of written informed consent, the recruited individuals will be instructed to complete a falls protocol referred to the month preceding the baseline visit, as well as a blood pressure (BP), bladder diary for up to 72 hours prior to the baseline visit. They will subsequently undergo a baseline examination including a comprehensive clinical, psychological and neuro-rehabilitation assessment, as well as an online semi-structured interview aimed at pinpointing the individual therapeutic needs and healthcare preferences. In case additional examinations are needed, these will be carried out on the same day of the baseline visit or, if not possible for individual or appointment reasons, at the earliest possible time point within the given timeframe as outlined in the visit schedule. Upon completion of the baseline visit and examinations, the individualized therapeutic plan, including mobile palliative care offer (for wheelchair-bound individuals) and guidance for self-practiced physio-, speech and occupational exercises will be prepared based on a standardized operational protocol drafted by the study team on the basis of published consensus recommendations, scientific evidence and principles of good clinical practice and adapted to the individual healthcare preferences and therapeutic needs of the recruited individuals.
Six, 12 and 18 months after the baseline visit, in-person visits will be scheduled, including a comprehensive clinical, psychological and neuro-rehabilitation re-assessment of the individual therapeutic needs. Therapeutic adaptations will be made following the standardized operational protocol and adapted to the individual healthcare preferences. In the event that the enrolled subjects are for legitimate reasons unable to travel to hospital, they will be offered the opportunity to complete the scheduled on-site assessments of month 6, 12, and 18 using the CHES online platform.
At month 12 the online semi-structured interview will be repeated to assess for eventual changes in the individual healthcare preferences due to the disease progression.
At month 1, 7 and 13, follow-up phone calls will be scheduled to verify the compliance with the individualized treatment plan and identify barriers to its application.
At month 1, 7, 13 and 18, the study participants will be invited to complete online satisfaction surveys with the overall individualized treatment plan.
Twenty-three patients will be block-wise randomized to receive additional monthly and on-demand neurological, psychological, physio-, occupational and speech therapy (based on individual needs) telemedicine visits through the CHES teleconsultation facility of the Tirol Kliniken.
Upon completion of the telemedicine visit (or on-demand mobile palliative interventions, for wheelchair-bound individuals, whenever needed and wished), brief satisfaction surveys will be sent to the study participants through the CHES platform.
Informal caregivers of the individuals with MSA recruited in the present study will be invited to participate upon written informed consent in an 18 months observational study, with baseline and 12 months semi-structured online interviews and baseline, 6-, 12- and 18 months assessment of their QoL and caregivers' burden.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple System Atrophy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Personalized best medical care.
Group Type
ACTIVE_COMPARATOR
Multidisciplinary, personalized symptomatic treatment
Intervention Type
OTHER
Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
Group 2
Personalized best medical care PLUS telemedicine
Group Type
EXPERIMENTAL
Telemedicine visits
Intervention Type
OTHER
Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
Multidisciplinary, personalized symptomatic treatment
Intervention Type
OTHER
Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telemedicine visits
Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
Intervention Type
OTHER
Multidisciplinary, personalized symptomatic treatment
Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For individuals with MSA:
* Age ≥30 years at the time of consent;
* Diagnosed with clinically probable or clinically established MSA according to the current MDS MSA criteria (1);
* Life-expectancy of at least 24 months as assessed by the investigator at the time of consent;
* Understands and agrees to comply with the study procedures and provides written informed consent (Note: a legal representative may NOT provide consent on behalf of the subject);
* Signed and dated informed consent document;
* Fluency in German;
* If not able to walk or stand without assistance/support at the time of consent, the participant lives in Tyrol or in another Austrian Region with available mobile palliative care.
For informal caregivers:
* Informal caregiver (i.e. person not receiving payment for his/her caregiving) of an individual with MSA recruited in the present study;
* Life-expectancy of at least 24 months as assessed by the investigator at the time of consent;
* Age≥ 18 years at the time of consent;
* Understands and agrees to provide information as outlined in the study protocol and to engage in semi-structured online interviews;
* Provides signed and dated written informed consent;
* Full legal capacity;
* Fluency in German.
* Age ≥30 years at the time of consent;
* Diagnosed with clinically probable or clinically established MSA according to the current MDS MSA criteria (1);
* Life-expectancy of at least 24 months as assessed by the investigator at the time of consent;
* Understands and agrees to comply with the study procedures and provides written informed consent (Note: a legal representative may NOT provide consent on behalf of the subject);
* Signed and dated informed consent document;
* Fluency in German;
* If not able to walk or stand without assistance/support at the time of consent, the participant lives in Tyrol or in another Austrian Region with available mobile palliative care.
For informal caregivers:
* Informal caregiver (i.e. person not receiving payment for his/her caregiving) of an individual with MSA recruited in the present study;
* Life-expectancy of at least 24 months as assessed by the investigator at the time of consent;
* Age≥ 18 years at the time of consent;
* Understands and agrees to provide information as outlined in the study protocol and to engage in semi-structured online interviews;
* Provides signed and dated written informed consent;
* Full legal capacity;
* Fluency in German.
Exclusion Criteria
For individuals with MSA
* Participation in an interventional clinical study at screening and throughout the study that would interfere with the MeDeMSA Care personalized treatment plan or would not permit telemedicine and mobile palliative care strategies;
* Charlson comorbidity index \>4 at the time of consent;
* Other major underlying medical conditions that may confound interpretation of study results as assessed by the investigator.
* Participation in an interventional clinical study at screening and throughout the study that would interfere with the MeDeMSA Care personalized treatment plan or would not permit telemedicine and mobile palliative care strategies;
* Charlson comorbidity index \>4 at the time of consent;
* Other major underlying medical conditions that may confound interpretation of study results as assessed by the investigator.
Minimum Eligible Age
30 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University Innsbruck
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessandra Fanciulli
Assoc. Prof. MD PhD
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alessandra Fanciulli, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Medizinische Universität Innsbruck
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Innsbruck Medical University
Innsbruck, Austria, Austria
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Austria
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma JA, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Hoglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord. 2022 Jun;37(6):1131-1148. doi: 10.1002/mds.29005. Epub 2022 Apr 21.
Reference Type
BACKGROUND
Wenning GK, Krismer F. Multiple system atrophy. Handb Clin Neurol. 2013;117:229-41. doi: 10.1016/B978-0-444-53491-0.00019-5.
Reference Type
BACKGROUND
Kwakkenbos L, Fransen J, Vonk MC, Becker ES, Jeurissen M, van den Hoogen FH, van den Ende CH. A comparison of the measurement properties and estimation of minimal important differences of the EQ-5D and SF-6D utility measures in patients with systemic sclerosis. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):50-6. Epub 2013 Jul 22.
Reference Type
BACKGROUND
Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015 Jan 15;372(3):249-63. doi: 10.1056/NEJMra1311488. No abstract available.
Reference Type
BACKGROUND
Cortelli P, Calandra-Buonaura G, Benarroch EE, Giannini G, Iranzo A, Low PA, Martinelli P, Provini F, Quinn N, Tolosa E, Wenning GK, Abbruzzese G, Bower P, Alfonsi E, Ghorayeb I, Ozawa T, Pacchetti C, Pozzi NG, Vicini C, Antonini A, Bhatia KP, Bonavita J, Kaufmann H, Pellecchia MT, Pizzorni N, Schindler A, Tison F, Vignatelli L, Meissner WG. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019 Oct 1;93(14):630-639. doi: 10.1212/WNL.0000000000008208.
Reference Type
BACKGROUND
Calandra-Buonaura G, Alfonsi E, Vignatelli L, Benarroch EE, Giannini G, Iranzo A, Low PA, Martinelli P, Provini F, Quinn N, Tolosa E, Wenning GK, Abbruzzese G, Bower P, Antonini A, Bhatia KP, Bonavita J, Pellecchia MT, Pizzorni N, Tison F, Ghorayeb I, Meissner WG, Ozawa T, Pacchetti C, Pozzi NG, Vicini C, Schindler A, Cortelli P, Kaufmann H. Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. Parkinsonism Relat Disord. 2021 May;86:124-132. doi: 10.1016/j.parkreldis.2021.03.027. Epub 2021 Mar 30.
Reference Type
BACKGROUND
Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG; ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018 Jun 1;39(21):1883-1948. doi: 10.1093/eurheartj/ehy037. No abstract available.
Reference Type
BACKGROUND
Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 Aug;264(8):1567-1582. doi: 10.1007/s00415-016-8375-x. Epub 2017 Jan 3.
Reference Type
BACKGROUND
Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, Karsenty G, Kessler TM, Schneider M, 't Hoen L, Blok B. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol. 2016 Feb;69(2):324-33. doi: 10.1016/j.eururo.2015.07.071. Epub 2015 Aug 22.
Reference Type
BACKGROUND
Jordan J, Fanciulli A, Tank J, Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi G, Hilz MJ, Kaufmann H, Lahrmann H, Mancia G, Mayer G, Norcliffe-Kaufmann L, Pavy-Le Traon A, Raj SR, Robertson D, Rocha I, Reuter H, Struhal W, Thijs RD, Tsioufis KP, Gert van Dijk J, Wenning GK, Biaggioni I. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens. 2019 Aug;37(8):1541-1546. doi: 10.1097/HJH.0000000000002078.
Reference Type
BACKGROUND
Randerath W, Verbraecken J, Andreas S, Arzt M, Bloch KE, Brack T, Buyse B, De Backer W, Eckert DJ, Grote L, Hagmeyer L, Hedner J, Jennum P, La Rovere MT, Miltz C, McNicholas WT, Montserrat J, Naughton M, Pepin JL, Pevernagie D, Sanner B, Testelmans D, Tonia T, Vrijsen B, Wijkstra P, Levy P. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017 Jan 18;49(1):1600959. doi: 10.1183/13993003.00959-2016. Print 2017 Jan.
Reference Type
BACKGROUND
Jasemi M, Valizadeh L, Zamanzadeh V, Keogh B. A Concept Analysis of Holistic Care by Hybrid Model. Indian J Palliat Care. 2017 Jan-Mar;23(1):71-80. doi: 10.4103/0973-1075.197960.
Reference Type
BACKGROUND
Hepgul N, Wilson R, Yi D, Evans C, Bajwah S, Crosby V, Wilcock A, Lindsay F, Byrne A, Young C, Groves K, Smith C, Burman R, Chaudhuri KR, Silber E, Higginson IJ, Gao W. Immediate versus delayed short-term integrated palliative care for advanced long-term neurological conditions: the OPTCARE Neuro RCT. Southampton (UK): NIHR Journals Library; 2020 Sep. Available from http://www.ncbi.nlm.nih.gov/books/NBK561537/
Reference Type
BACKGROUND
van Vliet LM, Gao W, DiFrancesco D, Crosby V, Wilcock A, Byrne A, Al-Chalabi A, Chaudhuri KR, Evans C, Silber E, Young C, Malik F, Quibell R, Higginson IJ; OPTCARE Neuro. How integrated are neurology and palliative care services? Results of a multicentre mapping exercise. BMC Neurol. 2016 May 10;16:63. doi: 10.1186/s12883-016-0583-6.
Reference Type
BACKGROUND
Adams JL, Myers TL, Waddell EM, Spear KL, Schneider RB. Telemedicine: A valuable tool in neurodegenerative diseases. Curr Geriatr Rep. 2020 Jun;9(2):72-81. doi: 10.1007/s13670-020-00311-z. Epub 2020 Mar 14.
Reference Type
BACKGROUND
Borders JC, Sevitz JS, Malandraki JB, Malandraki GA, Troche MS. Objective and Subjective Clinical Swallowing Outcomes via Telehealth: Reliability in Outpatient Clinical Practice. Am J Speech Lang Pathol. 2021 Mar 26;30(2):598-608. doi: 10.1044/2020_AJSLP-20-00234. Epub 2021 Feb 8.
Reference Type
BACKGROUND
Morris ME, Slade SC, Wittwer JE, Blackberry I, Haines S, Hackney ME, McConvey VB. Online Dance Therapy for People With Parkinson's Disease: Feasibility and Impact on Consumer Engagement. Neurorehabil Neural Repair. 2021 Dec;35(12):1076-1087. doi: 10.1177/15459683211046254. Epub 2021 Sep 29.
Reference Type
BACKGROUND
Tamplin J, Morris ME, Baker FA, Sousa TV, Haines S, Dunn S, Tull V, Vogel AP. ParkinSong Online: protocol for a telehealth feasibility study of therapeutic group singing for people with Parkinson's disease. BMJ Open. 2021 Dec 20;11(12):e058953. doi: 10.1136/bmjopen-2021-058953.
Reference Type
BACKGROUND
Vellata C, Belli S, Balsamo F, Giordano A, Colombo R, Maggioni G. Effectiveness of Telerehabilitation on Motor Impairments, Non-motor Symptoms and Compliance in Patients With Parkinson's Disease: A Systematic Review. Front Neurol. 2021 Aug 26;12:627999. doi: 10.3389/fneur.2021.627999. eCollection 2021.
Reference Type
BACKGROUND
Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980 Dec;20(6):649-55. doi: 10.1093/geront/20.6.649. No abstract available.
Reference Type
BACKGROUND
Miyashita M, Narita Y, Sakamoto A, Kawada N, Akiyama M, Kayama M, Suzukamo Y, Fukuhara S. Care burden and depression in caregivers caring for patients with intractable neurological diseases at home in Japan. J Neurol Sci. 2009 Jan 15;276(1-2):148-52. doi: 10.1016/j.jns.2008.09.022. Epub 2008 Oct 26.
Reference Type
BACKGROUND
Wiblin L, Lee M, Burn D. Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. Parkinsonism Relat Disord. 2017 Jan;34:7-14. doi: 10.1016/j.parkreldis.2016.10.013. Epub 2016 Oct 19.
Reference Type
BACKGROUND
Gallop K, Pham N, Maclaine G, Saunders E, Black B, Hubig L, Acaster S. Health-related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension. Neurodegener Dis Manag. 2023 Feb;13(1):35-45. doi: 10.2217/nmt-2022-0015. Epub 2022 Nov 16.
Reference Type
BACKGROUND
Dayal AM, Jenkins ME, Jog MS, Kimpinski K, MacDonald P, Gofton TE. Palliative Care Discussions in Multiple System Atrophy: A Retrospective Review. Can J Neurol Sci. 2017 May;44(3):276-282. doi: 10.1017/cjn.2016.439. Epub 2017 Feb 7.
Reference Type
BACKGROUND
Strupp J, Kunde A, Galushko M, Voltz R, Golla H. Severely Affected by Parkinson Disease: The Patient's View and Implications for Palliative Care. Am J Hosp Palliat Care. 2018 Apr;35(4):579-585. doi: 10.1177/1049909117722006. Epub 2017 Jul 26.
Reference Type
BACKGROUND
Wiblin L, Durcan R, Lee M, Brittain K. The Importance of Connection to Others in QoL in MSA and PSP. Parkinsons Dis. 2017;2017:5283259. doi: 10.1155/2017/5283259. Epub 2017 Sep 28.
Reference Type
BACKGROUND
Bloem BR, Henderson EJ, Dorsey ER, Okun MS, Okubadejo N, Chan P, Andrejack J, Darweesh SKL, Munneke M. Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. Lancet Neurol. 2020 Jul;19(7):623-634. doi: 10.1016/S1474-4422(20)30064-8. Epub 2020 May 25.
Reference Type
BACKGROUND
Pinto S, Caldeira S, Martins JC. e-Health in palliative care: review of literature, Google Play and App Store. Int J Palliat Nurs. 2017 Aug 2;23(8):394-401. doi: 10.12968/ijpn.2017.23.8.394.
Reference Type
BACKGROUND
Chan LML, Yan OY, Lee JJJ, Lam WWT, Lin CC, Auyeung M, Bloem BR, Kwok JYY. Effects of Palliative Care for Progressive Neurologic Diseases: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2023 Feb;24(2):171-184. doi: 10.1016/j.jamda.2022.11.001. Epub 2022 Dec 5.
Reference Type
BACKGROUND
Coon EA, Golden EP, Bryarly M, McGregor T, Nguyen BN, Moutvic MA, Cutsforth-Gregory JK, Stevens PM, Chou CZ, Rhee L, Vernino S. A call for multiple system atrophy centers of excellence. Clin Auton Res. 2022 Jun;32(3):205-208. doi: 10.1007/s10286-022-00866-1. Epub 2022 May 12. No abstract available.
Reference Type
BACKGROUND
Pillas M, Selai C, Quinn NP, Lees A, Litvan I, Lang A, Bower J, Burn D, Low P, Schrag A. Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Qual Life Res. 2016 Jan;25(1):81-8. doi: 10.1007/s11136-015-1071-y. Epub 2015 Aug 12.
Reference Type
BACKGROUND
Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):67-73. doi: 10.1136/jnnp.69.1.67.
Reference Type
BACKGROUND
Schrag A, Selai C, Mathias C, Low P, Hobart J, Brady N, Quinn NP. Measuring health-related quality of life in MSA: the MSA-QoL. Mov Disord. 2007 Dec;22(16):2332-8. doi: 10.1002/mds.21649.
Reference Type
BACKGROUND
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
Reference Type
BACKGROUND
Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012 Dec;87(12):1196-201. doi: 10.1016/j.mayocp.2012.10.013.
Reference Type
BACKGROUND
Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001 Jul;2(4):297-307. doi: 10.1016/s1389-9457(00)00065-4.
Reference Type
BACKGROUND
Frauscher B, Ehrmann L, Zamarian L, Auer F, Mitterling T, Gabelia D, Brandauer E, Delazer M, Poewe W, Hogl B. Validation of the Innsbruck REM sleep behavior disorder inventory. Mov Disord. 2012 Nov;27(13):1673-8. doi: 10.1002/mds.25223.
Reference Type
BACKGROUND
Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008 May;108(5):812-21. doi: 10.1097/ALN.0b013e31816d83e4.
Reference Type
BACKGROUND
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
Reference Type
BACKGROUND
Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006 Oct;22(10):1911-20. doi: 10.1185/030079906X132488.
Reference Type
BACKGROUND
Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W; Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004 Dec;19(12):1391-402. doi: 10.1002/mds.20255.
Reference Type
BACKGROUND
Ende J, Kazis L, Ash A, Moskowitz MA. Measuring patients' desire for autonomy: decision making and information-seeking preferences among medical patients. J Gen Intern Med. 1989 Jan-Feb;4(1):23-30. doi: 10.1007/BF02596485.
Reference Type
BACKGROUND
Dillen K, Goereci Y, Dunkl V, Muller A, Fink GR, Voltz R, Hocaoglu M, Warnke C, Golla H. Cultural adaptation of the Integrated Palliative care Outcome Scale for neurological symptoms. Palliat Support Care. 2023 Dec;21(6):1059-1068. doi: 10.1017/S1478951523000238.
Reference Type
BACKGROUND
Hawthorne G, Sansoni J, Hayes L, Marosszeky N, Sansoni E. Measuring patient satisfaction with health care treatment using the Short Assessment of Patient Satisfaction measure delivered superior and robust satisfaction estimates. J Clin Epidemiol. 2014 May;67(5):527-37. doi: 10.1016/j.jclinepi.2013.12.010.
Reference Type
BACKGROUND
da Silva BA, Faria CDCM, Santos MP, Swarowsky A. Assessing Timed Up and Go in Parkinson's disease: Reliability and validity of Timed Up and Go Assessment of biomechanical strategies. J Rehabil Med. 2017 Nov 21;49(9):723-731. doi: 10.2340/16501977-2254.
Reference Type
BACKGROUND
Lang JT, Kassan TO, Devaney LL, Colon-Semenza C, Joseph MF. Test-Retest Reliability and Minimal Detectable Change for the 10-Meter Walk Test in Older Adults With Parkinson's disease. J Geriatr Phys Ther. 2016 Oct-Dec;39(4):165-70. doi: 10.1519/JPT.0000000000000068.
Reference Type
BACKGROUND
Perez-Lloret S, van de Warrenburg B, Rossi M, Rodriguez-Blazquez C, Zesiewicz T, Saute JAM, Durr A, Nishizawa M, Martinez-Martin P, Stebbins GT, Schrag A, Skorvanek M; members of the MDS Rating Scales Review Committee. Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. Mov Disord. 2021 Feb;36(2):283-297. doi: 10.1002/mds.28313. Epub 2020 Oct 6.
Reference Type
BACKGROUND
Alonso CCG, de Freitas PB, Pires RS, De Oliveira DL, Freitas SMSF. Exploring the ability of strength and dexterity tests to detect hand function impairment in individuals with Parkinson's disease. Physiother Theory Pract. 2023 Feb;39(2):395-404. doi: 10.1080/09593985.2021.2013371. Epub 2021 Dec 12.
Reference Type
BACKGROUND
Ona ED, Jardon A, Cuesta-Gomez A, Sanchez-Herrera-Baeza P, Cano-de-la-Cuerda R, Balaguer C. Validity of a Fully-Immersive VR-Based Version of the Box and Blocks Test for Upper Limb Function Assessment in Parkinson's Disease. Sensors (Basel). 2020 May 13;20(10):2773. doi: 10.3390/s20102773.
Reference Type
BACKGROUND
De Dobbeleer L, Beyer I, Hansen AM, Molbo D, Mortensen EL, Lund R, Bautmans I. Grip Work Measurement with the Jamar Dynamometer: Validation of a Simple Equation for Clinical Use. J Nutr Health Aging. 2019;23(2):221-224. doi: 10.1007/s12603-019-1155-4.
Reference Type
BACKGROUND
Bartolome G, Starrost U, Schroter-Morasch H, Schilling B, Fischbacher L, Kues L, Graf S, Ziegler W. Validation of the Munich Swallowing Score (MUCSS) in patients with neurogenic dysphagia: A preliminary study. NeuroRehabilitation. 2021;49(3):445-457. doi: 10.3233/NRE-210011.
Reference Type
BACKGROUND
Eschlbock S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna). 2017 Dec;124(12):1567-1605. doi: 10.1007/s00702-017-1791-y. Epub 2017 Oct 22.
Reference Type
BACKGROUND
Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Kollensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W; European Multiple System Atrophy Study Group. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013 Mar;12(3):264-74. doi: 10.1016/S1474-4422(12)70327-7. Epub 2013 Feb 5.
Reference Type
BACKGROUND
Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012 Sep-Oct;32(5):690-700. doi: 10.1177/0272989X12455463.
Reference Type
BACKGROUND
Drummond MF, Schwartz JS, Jonsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discussion 362-8. doi: 10.1017/S0266462308080343.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1225/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Feasibility and Reliability of Multimodal Evoked Potentials
NCT03686826
COMPLETED
Telerehabilitation for Multiple Sclerosis
NCT06871072
COMPLETED
NA
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
NCT01214317
COMPLETED
NA
Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis
NCT02440516
COMPLETED
NA
Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis
NCT04979546
COMPLETED
NA
Home Rehabilitation As Continuity of Care in MS
NCT06699095
RECRUITING
NA
Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Biomarkers
NCT05561621
COMPLETED
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
NCT07032246
ENROLLING_BY_INVITATION
NA
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
NCT01142583
COMPLETED
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod
NCT02335892
COMPLETED
Internet-based Physical Activity Promotion and Exercise Prescription for People With Multiple Sclerosis (Feasibility Study)
NCT04057066
COMPLETED
NA
Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study
NCT02137044
COMPLETED
NA
Upper Limbs Intervention in Multiple Sclerosis
NCT02047825
COMPLETED
NA
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment
NCT03806387
COMPLETED
Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis
NCT01704183
COMPLETED
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
NCT01435993
TERMINATED
PHASE1
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975
RECRUITING
NA
Artificial Intelligence in Predicting Progression in Multiple Sclerosis Study
NCT05426980
COMPLETED
Fingolimod -Response According to Coping - Evaluation
NCT01420055
COMPLETED
PHASE4
Study Evaluating Mitoxantrone in Multiple Sclerosis
NCT00146159
TERMINATED
PHASE3
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
NCT00241254
COMPLETED
PHASE3
Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis
NCT04450030
UNKNOWN
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
NCT06280755
RECRUITING
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis
NCT03793868
COMPLETED
EARLY_PHASE1